DLin-KC2-DMA 是一种可电离阳离子脂质 (pKa≈6),对抗原呈递细胞 (APCs) 几乎无毒性。DLin-KC2-DMA 与纳米脂质颗粒(LNP) 结合后,可产生明显的 siRNA 介导的GAPDH基因沉默。DLin-KC2-DMA 可用于 siRNA 传递的研究。
生物活性 | DLin-KC2-DMA is an ionisable cationic lipid (pKa≈6) that is virtually non-toxic to antigen presenting cells (APCs). DLin-KC2-DMA produces significant siRNA-mediated gene silencing ofGAPDH, when binds to lipid nanoparticles (LNP). DLin-KC2-DMA can be used in siRNA delivery studies[1][2]. |
体外研究 (In Vitro) | DLin-KC2-DMA (1, 5 μg; 72 h) effectively produces a significant siRNA-mediated GAPDH gene silencing in both macrophages and dendritic cells[1]. DLin-KC2-DMA (24 h) exhibits high uptake into macrophages and dendritic cells[1]. DLin-KC2-DMA efficiently promotes release of encapsulated siRNA into the cytosol following uptake via the endocytotic pathway[1]. DLin-KC2-DMA displays almost no toxicity in primary APCs[1].
Cell Cytotoxicity Assay[1] Cell Line: | Macrophages, dendritic cells | Concentration: | 5 μg/mL (DLin-KC2-DMA contained-LNPs) | Incubation Time: | 72 h | Result: | Displayed almost no toxicity. |
Western Blot Analysis[1] Cell Line: | Macrophages, dendritic cells | Concentration: | 1, 5 μg | Incubation Time: | 72 h | Result: | Exhibited significant GAPDH silencing of more than 60% at 1 μg and of 80% at 5 μg in macrophages. Significantly reduced GAPDH protein and exhibited the silencing effects of 83% at 5 μg. |
|
体内研究 (In Vivo) | DLin-KC2-DMA contained-LNP siRNA systems (5 mg/kg; i.v.; single) effectively silences target genes in APcs in vivo[1].
Animal Model: | Naive C57BL/6 mice[1]. | Dosage: | 3 or 5 mg/kg (DLin-KC2-DMA contained-LNPs) | Administration: | Intravenous injection; single. | Result: | Significantly reduced GAPDH production in peritoneal cavity macrophages and dendritic cells and in the spleen-derived APCs when at 5 mg/kg. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | -20°C, stored under nitrogen *该产品在溶液状态不稳定,建议您现用现配,即刻使用。 |
溶解性数据 | In Vitro: DMSO : 100 mg/mL(155.74 mM;Need ultrasonic) Ethanol : 100 mg/mL(155.74 mM;Need ultrasonic) 配制储备液 1 mM | 1.5574 mL | 7.7871 mL | 15.5741 mL | 5 mM | 0.3115 mL | 1.5574 mL | 3.1148 mL | 10 mM | 0.1557 mL | 0.7787 mL | 1.5574 mL |
*请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.89 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.89 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (3.89 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|